Aurora Therapeutics

Aurora Therapeutics was launched to solve the fundamental scalability problem in rare disease treatment, where over 350 million people worldwide lack therapies targeting their specific genetic mutations. The company is developing a platform that leverages CRISPR gene editing tools, which can be rapidly tailored to specific mutations with increasing precision, to create personalized treatments at scale. Led by CEO Edward M. Kaye and backed by investors like Menlo Ventures, Aurora is assembling a team of leaders in gene editing, rare-disease medicine, and therapeutic development to realize the potential of personalized gene editing for millions of patients.

A scalable platform for personalized CRISPR-based gene editing that can be rapidly tailored to specific genetic mutations, designed to enable many-at-a-time development of therapies for rare disease variants.

Total raised: $110.6M

Aurora faces competition from established CRISPR companies like CRISPR Therapeutics and Editas Medicine, as well as rare disease specialists like Sarepta Therapeutics and Ultragenyx. However, Aurora's unique focus on creating a scalable platform for personalized gene editing, rather than developing individual therapies, represents a novel approach that could differentiate it in the market if successfully executed.